Repository logo


The importance of HIFAR to nuclear medicine

Simple item page
dc.contributor.authorWood, NRen_AU
dc.date.accessioned2026-01-27T23:40:36Zen_AU
dc.date.issued1997-10-16en_AU
dc.date.statistics2025-01-13en_AU
dc.descriptionPhysical copy held by ANSTO Library at DDC: 621.48/9en_AU
dc.description.abstractSince its official opening on 26 January 1960, the HIFAR research reactor operated by the Australian Nuclear Science and Technology Organisation (ANSTO) at Lucas Heights near Sydney has been used to support an expanding nuclear medicine market. HIFAR has characteristics which make it very suitable for this role and the effect has been to make ANSTO the dominant supplier of reactor-based radiopharmaceuticals in Australia and a significant exporter. While HIFAR has capacity to support limited increased production, its future requires government decisions. The author concluded that the absence of an operational research reactor in Australia and the lack of another local source of neutrons could directly affect the practice of nuclear medicine in the country and the level of presently increasing exports.en_AU
dc.identifier.booktitleANA 97: second conference on nuclear science & engineering in Australia, 1997, Millennium Sydney, 16-17 October 1997. Conference handbooken_AU
dc.identifier.citationWood, N. R. (1997). The importance of HIFAR to nuclear medicine. Paper presented to ANA 97 "Second Conference on Nuclear Science & Engeering in Australia, Sydney, 16-17 October 1997. In ANA 97: second conference on nuclear science & engineering in Australia, 1997, Millennium Sydney, 16-17 October 1997. Conference handbook, (pp. 52-54), Canberra, ACT: Australian Nuclear Association.en_AU
dc.identifier.conferenceenddate1997-10-17en_AU
dc.identifier.conferencenameANA 97: second conference on nuclear science & engineering in Australia, 1997, Millennium Sydney, 16-17 October 1997. Conference handbooken_AU
dc.identifier.conferenceplaceCanberra, ACTen_AU
dc.identifier.conferencestartdate1997-10-16en_AU
dc.identifier.isbn0949188107en_AU
dc.identifier.pagination52-54en_AU
dc.identifier.placeofpublicationCanberra, ACTen_AU
dc.identifier.urihttps://apo.ansto.gov.au/handle/10238/16983en_AU
dc.language.isoenen_AU
dc.publisherAustralian Nuclear Associationen_AU
dc.subjectHIFAR Reactoren_AU
dc.subjectANSTOen_AU
dc.subjectAustralian organizationsen_AU
dc.subjectNuclear medicineen_AU
dc.subjectRadiopharmaceuticalsen_AU
dc.subjectProductionen_AU
dc.subjectNeutronsen_AU
dc.subjectBromine 82en_AU
dc.subjectChromium 51en_AU
dc.subjectCommercializationen_AU
dc.subjectCopper 64en_AU
dc.subjectExportsen_AU
dc.subjectIsotope productionen_AU
dc.subjectMarketen_AU
dc.subjectNeutron source facilitiesen_AU
dc.subjectRadioisotope generatorsen_AU
dc.subjectTechnetium 99en_AU
dc.subjectYtterbiumen_AU
dc.subjectYears living radioisotopesen_AU
dc.titleThe importance of HIFAR to nuclear medicineen_AU
dc.typeConference Paperen_AU

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
29016311.pdf
Size:
103.64 KB
Format:
Adobe Portable Document Format
Download

License bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
1.63 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Conference Publications